Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

NCT04685590 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer Disease, Early Onset
Mild Cognitive Impairment

Interventions

DRUG: Dasatinib + Quercetin
OTHER: Placebo Capsules

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]